Liquid Biopsy to Reduce Time to Treatment for Advanced Nonsquamous NSCLC Diagnosed at Outside Sites
The purpose of this study is to determine if liquid biopsies will reduce time to begin treatment in participants with non-small cell lung cancer (NSCLC). A liquid biopsy is a test done on a sample of blood to look for cancer cells.
Checked against the public recordLast updated Feb 5, 2025 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Diagnostic
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Case Comprehensive Cancer Center
- Interventions being studied
- Diagnostic Test: Liquid biopsy
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Participants with newly diagnosed, advanced nonsquamous NSCLC referred to the Cleveland Clinic Taussig Cancer Center from outside centers without prior testing results available for targetable genetic alterations * Plan to receive systemic therapy at the Cleveland Clinic, OR plan to receive systemic therapy at an outside site while maintaining either intermittent follow up at Cleveland Clinic or with electronic health record access through Care Everywhere. Exclusion Criteria: * Prior therapy for this diagnosis of NSCLC * Prior adequate molecular testing done for the current diagnosis of NSCLC
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Cleveland Clinic, Case Comprehensive Cancer CenterCleveland, Ohio
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 5, 2025. Always confirm current availability with the study team.